June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Regenerative Potential of Stem Cell-Derived Exosomes
Author Affiliations & Notes
  • Golnar Shojaati
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
    Ophthalmology, University of Zurich, Zurich, Switzerland
  • Martha L Funderburgh
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Mary Mann
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Irona Khandaker
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • James L Funderburgh
    Ophthalmology, University of Pittsburgh, Pittsburgh, Pennsylvania, United States
  • Footnotes
    Commercial Relationships   Golnar Shojaati, None; Martha Funderburgh, None; Mary Mann, None; Irona Khandaker, None; James Funderburgh, None
  • Footnotes
    Support  DoD Award: MR130197, NIH Grant EY016415, P30-EY008098, Research to Prevent Blindness, Eye and Ear Foundation of Pittsburgh
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3373. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Golnar Shojaati, Martha L Funderburgh, Mary Mann, Irona Khandaker, James L Funderburgh; Regenerative Potential of Stem Cell-Derived Exosomes. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3373.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose : Mesenchymal stem cells from human corneal stroma (CSSC) have been shown to induce regeneration of transparent stromal tissue during wound repair in mice. Exosomes, nano-sized extracellular vesicles, have recently been implicated in the ability of bone marrow mesenchymal stem cells to repair damaged tissue. In this study we examined the hypothesis that exosomes produced by CSSC can prevent corneal scarring in a manner similar to that of the live CSSC cells.

Methods : Passage 3-4 CSSC and HEK (human embryonic kidney) cells were cultured 48 hr in exosome-free medium, and exosomes isolated from the conditioned medium using polymer based precipitation followed by ultracentrifugation at 100,000 x g. Exosomes were characterized using Nanosight light scattering, transmission electron microscopy (TEM), and flow cytometry. Suppression of scarring was examined in a mouse model of corneal wound healing with exosomes in a fibrin gel applied at the time of wounding. Scar area 14 days after wounding was calculated in a masked fashion from ex-vivo light microscope images. Mouse corneal fibrotic gene expression was examined by qPCR. Neutrophil infiltration was assessed by ELISA for myeloperoxidase at 48 hr after wounding. Statistical significance was determined with t-test and Dunn’s test analysis using p<0.05 as a criterion.

Results : Isolated exosomes from CSSC were microvesicles of 20-200 nm as visualized by TEM and light scattering. Flow cytometry found both CD63 and CD81 on the exosome surface. Addition of exosomes to corneal wounds produced a significant reduction of stromal scar area compared to control wounds and wounds treated with exosomes produced by HEK cells (p<0.001, n=8). CSSC exosomes completely suppressed neutrophil infiltration into wounds at 24 hr (p<0.001, n=8). At 14 days, expression of fibrotic markers (Tnc, Acta2, Col3a1, Sparc) was significantly reduced in CSSC-exosome treated wounds (p<0.05, n=4), to a level similar to that of unwounded tissue.

Conclusions : Exosomes derived from CSSC (but not those of HEK cells) embody a high regenerative potential. In vivo, they suppressed inflammation and prevented corneal scarring and fibrosis in a mouse wounding model. These results suggest that exosomes may allow a non-cell based therapy for corneal scars in the future.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.


This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.